

**UNIVERSITI TEKNOLOGI MARA**

**PHARMACOKINETICS OF GENTAMICIN IN  
PEDIATRICS HOSPITALIZED PATIENTS**

**NORDIYANA BINTI SHADOM**

**Dissertation submitted in partial fulfillment of the requirement  
for the Bachelor of Pharmacy (Hons.)**

**Faculty of Pharmacy**

**2012**

## **ACKNOWLEDGEMENT**

All the praise and glory to Allah Almighty Who blessed has blessed me with good health and strength to complete my project successfully in time. I wish to express my heartiest gratitude to my supervisor, Prof. Dr. Mohamed Mansor Manan for his invaluable guidance, insightful advice and motivational support throughout this research.

I would like to offer a lot of gratitude to Puan Asmawarni, the TDM Pharmacist and all staffs from Clinical Pharmacokinetic Services Unit, HTAR Klang and also Clinical Pharmacokinetic Services Unit, HSA Johor Bharu for all their cooperation and support.

It will be unfair not to mention the appreciated encouragement received from my colleague, Nurul Ashikin in finishing this study. This study would have not been a success without the prayers and support from my beloved family and friends.

# TABLE OF CONTENTS

<b>List of contents</b>	<b>Page</b>
<b>TITLE PAGE</b>	
<b>ACKNOWLEDGEMENT</b>	ii
<b>TABLE OF CONTENTS</b>	iii
<b>LIST OF TABLES</b>	v
<b>LIST OF FIGURES</b>	vi
<b>LIST OF ABBREVIATIONS</b>	vii
<b>ABSTRACT</b>	xiii
<b>CHAPTER ONE (INTRODUCTION)</b>	
1.1 Problem statement	1
1.2 Objective	1
1.3 Significance of the study	2
1.4 Hypothesis	2
1.5 Introduction of therapeutic drug monitoring	2
<b>CHAPTER TWO (LITERATURE REVIEW)</b>	
2.1 Introduction to pediatric	5
2.2 Aminoglycoside	6
2.3 Gentamicin	7
2.3.1 Chemical structure	8
2.3.2 Mechanism of action	10
2.3.3 Pharmacokinetics of gentamicin	12
2.3.4 Toxicity	13
2.4 Population pharmacokinetic	19
2.5 Therapeutic Drug Monitoring	24
2.5.1 Procedure for therapeutic drug monitoring	27
2.6 Theories on therapeutic drug monitoring	28
2.6.1 Pharmacokinetic model	28
2.6.2 One-compartment model	29
2.6.3 Clearance	31
2.6.4 Elimination rate constant	33
2.6.5 Volume of distribution	33
2.6.6 Half-life ( $t^{1/2}$ )	34
	iii

2.6.7 Area under the Curve (AUC)	35
2.7 Pharmaceutical Care	35
<b>CHAPTER THREE (METHODOLOGY)</b>	
3.1 Patients	37
3.2 Parameter	38
3.3 Administration and Sampling time	38
3.4 Analytical technique	40
3.5 Gentamicin kinetic	40
3.6 Data analysis	40
<b>CHAPTER FOUR (RESULT)</b>	
4.1 Demographic result	41
4.2 Data result	45
<b>CHAPTER FIVE (DISCUSSION)</b>	83
5.1 Comparison with Siber <i>et al</i> , 1975	86
5.2 Comparison with Bass <i>et al</i> , 1998	86
<b>CHAPTER SIX (CONCLUSION)</b>	88
<b>BIBLIOGRAPHY</b>	90
<b>APPENDIX</b>	

## ABSTRACT

The purpose of this study was to study the effectiveness of pharmacokinetics monitoring and to establish a population pharmacokinetics in pediatric hospitalized patients. The data comprise of 34 patients; 23 of male patients and 11 of female patients. The TDM data that had been collected from these patients is 71 data. The patients had been divided into 3 group according to their age which is group 1 (6 months to 2 years), group 2 (2 years to 5 years) and group 3 (5 years to 12 years). The patient parameters including body weight, gender, age, creatinine clearance (ClCr) and serum electrolytes were analyzed to identify their potential influences on gentamicin pharmacokinetics. The data was best described with a one-compartment model. The data analysis showed that there is a strong relationship between  $K_e$  and volume of distribution ( $V_d$ ) with  $R^2$  value of 0.98, weight and clearance with  $R^2$  value of 0.99, and relationship between creatinine clearance (CrCl) and clearance of drug with  $R^2$  value is 0.917. The mean of  $K_e$ ,  $t_{1/2}$  and  $V_d$  in this study, were 0.18 hour<sup>-1</sup>, 4.31 hour and 0.54 L respectively. This analysis indicates that this population has a wide inter-patient variability and it necessitate the practice of routine therapeutic drug monitoring to ensure minimal adverse effect and maximum therapeutic effect to the patients.